These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 14719493)
41. After years of steady growth, winds of restraint blowing on prescription-drug industry. Robinson A CMAJ; 1995 Jul; 153(1):85-8. PubMed ID: 7796380 [TBL] [Abstract][Full Text] [Related]
42. Tiered formularies open the potential for lack of access to needed drugs. Manag Care; 2004 Nov; 13(11):53. PubMed ID: 15595403 [No Abstract] [Full Text] [Related]
43. [The costs of new drugs compared to current standard treatment]. Ujeyl M; Schlegel C; Gundert-Remy U Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023 [TBL] [Abstract][Full Text] [Related]
44. The economic and human impact of new drugs. Lichtenberg FR J Clin Psychiatry; 2003; 64 Suppl 17():15-8. PubMed ID: 14680422 [TBL] [Abstract][Full Text] [Related]
45. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Kay J; Feagan BG; Guirguis MS; Keystone EC; Klein AV; Lubiniecki AS; Mould DR; Nyarko KA; Ridgway AA; Trudeau ME; Wang J Biologicals; 2012 Nov; 40(6):517-27. PubMed ID: 23084808 [TBL] [Abstract][Full Text] [Related]
46. National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities. Yoongthong W; Hu S; Whitty JA; Wibulpolprasert S; Sukantho K; Thienthawee W; Han H; Scuffham PA Value Health; 2012; 15(1 Suppl):S126-31. PubMed ID: 22265059 [No Abstract] [Full Text] [Related]
47. The Emergency Drug Release Program: regulatory aspects of new drug access in Canada. Gilron I CMAJ; 1993 Apr; 148(7):1151-3. PubMed ID: 8457955 [No Abstract] [Full Text] [Related]
49. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558 [TBL] [Abstract][Full Text] [Related]
50. The Common Drug Review: a NICE start for Canada? McMahon M; Morgan S; Mitton C Health Policy; 2006 Aug; 77(3):339-51. PubMed ID: 16214257 [TBL] [Abstract][Full Text] [Related]
52. Military brings order to formulary system. Berberabe T Manag Care; 2004 Nov; 13(11):28-30. PubMed ID: 15595398 [No Abstract] [Full Text] [Related]
53. [Authorization and reimbursement of orphan drugs in an international comparison]. Roll K; Stargardt T; Schreyögg J Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380 [TBL] [Abstract][Full Text] [Related]
54. Reference based pricing for provincial drug benefit programs. McLaughlin PR Can J Cardiol; 1996 Jan; 12(1):16, 25-6. PubMed ID: 8595565 [No Abstract] [Full Text] [Related]
55. India tries to improve national system for handling clinical trials. Sharma DC Lancet; 2001 May; 357(9269):1682. PubMed ID: 11425387 [No Abstract] [Full Text] [Related]
56. Should Medicare adopt the Veterans Health Administration formulary? Frakt AB; Pizer SD; Feldman R Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191 [TBL] [Abstract][Full Text] [Related]
57. Saving money. A dozen prescription price tips. Roberts SS Diabetes Forecast; 2003 Aug; 56(8):73-5. PubMed ID: 15317077 [No Abstract] [Full Text] [Related]
58. PBS medications--improving access for Aboriginal and Torres Strait Islander peoples. Couzos S Aust Fam Physician; 2005 Oct; 34(10):841-4. PubMed ID: 16217569 [TBL] [Abstract][Full Text] [Related]
59. [Positive list of drugs and osteoporosis]. Krankenpfl J; 2003; 41(4-6):113. PubMed ID: 12929324 [No Abstract] [Full Text] [Related]
60. A review of health leadership and management capacity in the Solomon Islands. Asante A; Roberts G; Hall J Pac Health Dialog; 2012 Apr; 18(1):166-77. PubMed ID: 23240354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]